| John Pezzimenti, MD | |
|
24 Hospital Ave, Danbury, CT 06810-6099 | |
| (203) 797-7029 | |
| Not Available |
| Full Name | John Pezzimenti |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Hematology & Oncology |
| Location | 24 Hospital Ave, Danbury, Connecticut |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851333215 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 014475 (Connecticut) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| John Pezzimenti, MD 24 Hospital Ave, Danbury, CT 06810-6099 Ph: (203) 797-7029 | John Pezzimenti, MD 24 Hospital Ave, Danbury, CT 06810-6099 Ph: (203) 797-7029 |
News Archive
OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.
Chagas disease is the main cause of infectious heart disease in Latin America. Researchers from the INGEBI and IBYME Institutes in Argentina explored the effect of glycan binding protein interactions between the human host and Typanosoma cruzi parasite. They found that a glycan binding protein expressed in humans modified the infection in cells of the heart muscle, showing the importance of galectins in the response to parasite infection.
Roman Catholic leaders in New York City on Thursday released a joint statement criticizing the New York City Department of Health and Mental Hygiene's efforts to deliver about 26 million condoms to organizations and venues in the city to help curb the spread of HIV, the New York Post reports.
Bio Light Israeli Life Sciences Investments Ltd., an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions, announced today that its IOPtiMate system for the treatment of glaucoma has been approved by the Canadian Medical Devices Bureau, allowing the Company to commercialize the surgical system in Canada.
› Verified 6 days ago
Dr. Shivayogi V Magavi, MD Hematology & Oncology Medicare: May Accept Medicare Assignments Practice Location: 57 North St, Suite 103, Danbury, CT 06810 Phone: 203-744-7007 | |
Andrew Keller, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 27 Hospital Ave, Danbury, CT 06810 Phone: 203-797-7155 | |
Mary E. Blackman, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 79 Sand Pit Road, 102, Danbury, CT 06810 Phone: 203-749-5700 | |
Nirmalamma S Magavi, MD Hematology & Oncology Medicare: May Accept Medicare Assignments Practice Location: 57 North St, Suite 103, Danbury, CT 06810 Phone: 203-744-7007 | |
David D Weinshel, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 24 Hospital Ave, Danbury, CT 06810 Phone: 203-797-7173 | |
Dr. Michael Spiegel, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 33 Germantown Rd, 1st Floor, Danbury, CT 06810 Phone: 203-794-5600 Fax: 203-794-5611 | |
Michael Cohenuram, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 24 Hospital Ave, Danbury, CT 06810 Phone: 203-797-7742 Fax: 203-830-2090 |